421 related articles for article (PubMed ID: 37486577)
1. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
Hashimoto H; Takeuchi M; Kawakami K
Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
[TBL] [Abstract][Full Text] [Related]
2. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
5. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
6. Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Honda M; Horiuchi H; Torii T; Nakajima A; Iijima T; Murano H; Yamanaka H; Ito S
BMC Pediatr; 2021 Dec; 21(1):581. PubMed ID: 34922491
[TBL] [Abstract][Full Text] [Related]
7. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
[TBL] [Abstract][Full Text] [Related]
11. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
13. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
14. Impact of allopurinol use on urate concentration and cardiovascular outcome.
Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
17. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Guma M; Dadpey B; Coras R; Mikuls TR; Hamilton B; Quehenberger O; Thorisdottir H; Bittleman D; Lauro K; Reilly SM; Liu-Bryan R; Terkeltaub R
Arthritis Res Ther; 2022 Jul; 24(1):175. PubMed ID: 35879786
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
[TBL] [Abstract][Full Text] [Related]
20. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
